公开(公告)号：US20180228769A1

公开(公告)日：2018-08-16

申请号：US15516780

申请日：2015-09-29

Applicant: Pfizer Inc.

Inventor： Puja Sapra ,  Boris Shor

IPC: A61K31/40 ,  A61K47/68 ,  A61P35/00

CPC classification number: A61K31/40 ,  A61K31/166 ,  A61K31/337 ,  A61K31/4015 ,  A61K31/4025 ,  A61K45/06 ,  A61K47/6855 ,  A61K47/6857 ,  A61K2300/00 ,  A61P35/00

Abstract: This invention relates to combinations of an auristatin or an auristatin-based antibody-drug-conjugate (ADC) with second active agents including PI3K/mTOR inhibitors, MEK inhibitors, taxanes, or other anti-cancer agents, and methods of treating abnormal cell growth by administering these combinations to patients.